SML0472
4-IPP
≥97% (HPLC)
Synonym(s):
4-Iodo-6-phenylpyrimidine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C10H7IN2
CAS Number:
Molecular Weight:
282.08
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL (clear solution, warmed)
storage temp.
−20°C
SMILES string
Ic1cc(ncn1)-c2ccccc2
InChI
1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
InChI key
ZTCJXHNJVLUUMR-UHFFFAOYSA-N
Application
4-IPP has been used as a macrophage migration inhibitory factor (MIF) in conditioned medium (CM) for in vitro migration assay.
Biochem/physiol Actions
4-IPP is a cell permeable, potent macrophage migration inhibitory factor (MIF) antagonist that covalently modifies MIF N-terminal proline.
4-Iodo-6-phenylpyrimidine (4-IPP) has the potential to be a new anti-polyploid therapeutic agent that may be utilized in patients with thyroid cancer to target polyploid tumor cells. It suppresses osteoclastogenesis by blocking the IMF-κB pathway. 4-IPP can be employed as a therapeutic target for macrophage migration inhibitory factor (MIF) to treat pathologic osteolytic bone diseases and postmenopausal bone loss. It can prevent the development and motility of lung adenocarcinoma cells and can stimulate apoptosis and mitotic death of thyroid carcinomas.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Yuxin Zhang et al.
Aging, 13(4), 5804-5823 (2021-02-19)
Joint capsule fibrosis caused by excessive inflammation leading to post-traumatic joint contracture (PTJC). Fibroblasts trigger inflammation under the challenge of various proinflammatory cytokines. Macrophage migration inhibitory factor (MIF) is a prominent proinflammatory cytokine involved in inflammation- and fibrosis-associated pathophysiology, we
Sarah Maria Johler et al.
Cancer immunology, immunotherapy : CII, 65(12), 1465-1476 (2016-09-16)
Macrophage migration inhibitory factor (MIF) is known to be involved in oncogenic transformation, tumour progression, and immunosuppression and is overexpressed in many solid tumours, including paediatric rhabdomyosarcoma (RMS). We investigated the function of MIF in RMS during treatment with cytotoxic
Kavitha Yaddanapudi et al.
Cancer immunology research, 4(2), 101-112 (2015-11-26)
Highly aggressive cancers "entrain" innate and adaptive immune cells to suppress antitumor lymphocyte responses. Circulating myeloid-derived suppressor cells (MDSC) constitute the bulk of monocytic immunosuppressive activity in late-stage melanoma patients. Previous studies revealed that monocyte-derived macrophage migration inhibitory factor (MIF)
Nadège Kindt et al.
Journal of clinical medicine, 8(1) (2019-01-13)
Human papilloma virus (HPV) infection has been well-established as a risk factor in head and neck squamous cell carcinoma (HNSCC). The carcinogenic effect of HPV is mainly due to the E6 and E7 oncoproteins, which inhibit the functions of p53
Seul-Ki Cheon et al.
Molecular oncology, 12(8), 1398-1409 (2018-06-14)
Although MEK blockade has been highlighted as a promising antitumor drug, it has poor clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service